Dexcom stock received a raised price objective and rating restatement from analysts, accompanied by SEC filings.
1 report, 1 independent
Updated Sep 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Dexcom stock received a raised price objective and rating restatement from analysts, accompanied by SEC filings.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Dexcom
company that develops, manufactures and distributes continuous glucose monitoring systems
Nothing else this week.
-
Citigroup
American investment bank and financial services corporation
- Jefferies Financial Group raised its shares to strong-buy rating, while Citigroup raised its shares to outperform rating, and Norges Bank bought a new position in Essex Property Trust, Inc.
- Citigroup coordinates the international retail offering for Anthropic's IPO, with Goldman Sachs and Morgan Stanley taking on lead and stabilization roles.
-
Royal Bank of Canada
financial institution in Canada
Related events
- Benchmark boosted its price objective on DexCom shares on November 2, 2026.
- General Counsel of Arthur J. Gallagher & Co. sold company stock, while major banks issued rating and price target updates.
- RBC and Citigroup boosted price objectives on Lockheed Martin shares, with MarketBeat aggregating the analyst ratings.
- Royal Bank of Canada reiterated an outperform rating on Alfa Laval shares.
- Financial firms including Truist, RBC, TD Cowen, and Jefferies issued various rating updates on October 30, 2026.